Finance

Lists
AKTS:NASDAQ
Aktis Oncology Inc
17,90 US$
+0,93%
(+0,17) 1D
9 ოქტ, 13:55:16 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AKTS...
Open
17,74 US$
High
18,21 US$
Low
17,58 US$
Mkt. cap
962,33 მლნ.
Avg. vol.
426,64 ათ.
Volume
134,86 ათ.
52-wk high
34,19 US$
52-wk low
14,72 US$
EPS
-1,42 US$
Shares outstanding
53,75 მლნ.
No. of employees
79
Open
17,74 US$
High
18,21 US$
Low
17,58 US$
Mkt. cap
962,33 მლნ.
Avg. vol.
426,64 ათ.
Volume
134,86 ათ.
52-wk high
34,19 US$
52-wk low
14,72 US$
EPS
-1,42 US$
Shares outstanding
53,75 მლნ.
No. of employees
79
News stories
From web sources and news partners
About Aktis Oncology Inc
CEO-
Employees79
Founded2020
Headquartersბოსტონი, მასაჩუსეტსი, ამერიკის შეერთებული შტატები
Sector-
Analyst ratings
Based on 6 analysts giving stock ratings to AKTS in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AKTS in the last 3 months.
Highest
Current 17,90 US$
40,00 US$ (+123,40%)
Average
35,80 US$ (+99,94%)
Lowest
33,00 US$ (+84,31%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Nierengarten
Wedbush
Buy
Maintained
35,00 US$
+95,5%
10/02/2026
Jeff Jones
Oppenheimer
Buy
Initiated
40,00 US$
+123,4%
09/09/2026
David Lebowitz
BMO Capital
Buy
Initiated
37,00 US$
+106,6%
08/18/2026
Unknown Analyst
BMO Capital
Buy
Initiated
37,00 US$
+106,6%
08/18/2026
Alec Stranahan
Bank of America Securities
Buy
Maintained
34,00 US$
+89,9%
08/14/2026
Jessica Fye
J.P. Morgan
Buy
Reiterated
33,00 US$
+84,3%
08/14/2026
Alexandra Ramsey
William Blair
Buy
Maintained
-
-
08/14/2026
Christopher Raymond
Raymond James
Buy
Initiated
40,00 US$
+123,4%
06/16/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
35,00 US$
+95,5%
06/03/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/11/2026
Sami Corwin
William Blair
Buy
Initiated
18,75 US$
+4,7%
05/02/2026
Unknown Analyst
William Blair
Buy
Initiated
18,60 US$
+3,9%
04/29/2026
Andy Hsieh
William Blair
Buy
Initiated
32,00 US$
+78,7%
04/29/2026
Jonathan Chang
Leerink Partners
Buy
Initiated
31,00 US$
+73,1%
02/03/2026
Last report
13 აგვ. 2026
Fiscal period
Q2 2026
-0,44 US$ / -0,43 US$
-2,15%miss
Revenue / Est. (USD)
3,38 მლნ. / 2,58 მლნ.
+30,99%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ივნ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
1,60 მლნ.
1,87 მლნ.
3,23 მლნ.
3,38 მლნ.
Cost of goods sold
18,63 მლნ.
16,49 მლნ.
20,04 მლნ.
25,28 მლნ.
Cost of revenue
18,63 მლნ.
16,49 მლნ.
20,04 მლნ.
25,28 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,94 მლნ.
2,75 მლნ.
5,90 მლნ.
7,00 მლნ.
Operating expense
3,94 მლნ.
2,75 მლნ.
5,90 მლნ.
7,00 მლნ.
Total operating expenses
22,56 მლნ.
19,24 მლნ.
25,93 მლნ.
32,28 მლნ.
Operating income
-20,96 მლნ.
-17,38 მლნ.
-22,71 მლნ.
-28,90 მლნ.
Other non operating income
-20,00 ათ.
-11,00 ათ.
-3,00 ათ.
-10,00 ათ.
EBT including unusual items
-18,08 მლნ.
-15,14 მლნ.
-18,32 მლნ.
-24,14 მლნ.
EBT excluding unusual items
-18,08 მლნ.
-15,14 მლნ.
-18,32 მლნ.
-24,14 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-18,08 მლნ.
-15,14 მლნ.
-18,32 მლნ.
-24,14 მლნ.
Net profit margin
-1 128,98%
-809,52%
-567,86%
-713,48%
Earnings per share
-
-
-0,38
-0,44
Interest and investment income
2,91 მლნ.
2,25 მლნ.
4,38 მლნ.
4,76 მლნ.
Interest expense
-
-
-
-
Net interest expenses
2,91 მლნ.
2,25 მლნ.
4,38 მლნ.
4,76 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-20,41 მლნ.
-16,68 მლნ.
-22,05 მლნ.
-28,02 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები